Skip to content

Michelle Weiner

NeuroPain Health.

4 papers in the library · 9 citations · publishing 2023-2025

Papers

Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches.

Frontiers in pain research (Lausanne, Switzerland) January 1, 2023 Daniella Batievsky, Michelle Weiner, Shari B Kaplan et al. 8 citations

Ketamine-assisted psychotherapy (KAPT) may reduce symptoms in people with both chronic pain and major depressive disorder. In an observational pilot study, ten participants received either high-dose intramuscular ketamine before therapy (psychedelic approach) or low-dose sublingual lozenges during therapy (psycholytic approach). Depression, pain, anxiety, and PTSD symptoms declined in all participants over six sessions. The psychedelic group showed larger and more consistent decreases. No statistically significant differences between the two approaches were found, likely due to the small sample size. The findings suggest KAPT may be effective for this comorbidity, with the psychedelic approach possibly more beneficial.

Self-Reported Improvements in Comorbid Post-Traumatic Stress Disorder Symptoms, Depression, Anxiety, and Sleep Among Real-World Patients Receiving Medical Ketamine: Exploring the Role of Adjunct Therapies.

European journal of trauma & dissociation = Revue europeenne du trauma et de la dissociation September 1, 2025 Shahar Almog, Albert Garcia-Romeu, Kathryn A Walker et al. 1 citation

People with post-traumatic stress disorder (PTSD) who also have depression, anxiety, and sleep problems reported that ketamine treatment improved multiple PTSD symptoms, based on a survey of 202 real-world patients. Before starting ketamine, those with PTSD had more severe depression, anxiety, and sleep disturbance than those without PTSD, but after treatment their scores were no different, indicating they responded equally well. Most PTSD patients also received psychotherapy, but similar improvements occurred in those who did not. Patients described ketamine as allowing them to reprocess trauma and improve a range of symptoms.

Self-reported changes and experiences with substance use among real-world patients treated with medical ketamine.

Experimental and clinical psychopharmacology July 24, 2025 Shahar Almog, Maribel Rodriguez Perez, Deepthi S Varma et al.

In a survey of 201 patients receiving medical ketamine for psychiatric or pain conditions, most reported either a positive change (54.7%) or no change (44.3%) in their use of other substances. Those with a past history of problematic substance use showed significantly greater reductions than those with present or no such history. Patients described reduced craving, less need to self-medicate, and increased motivation to quit substances. Ketamine did not appear to induce or increase drug use among those with minimal or no prior use, though some reported risky behaviors such as using other psychedelics or substituting alcohol with recreational ketamine. Further research is needed to identify and protect at-risk patients.

Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series.

Frontiers in pain research (Lausanne, Switzerland) January 1, 2025 Shahar Almog, Michelle Weiner, Jessica N Howarth et al.

Chronic pain involves both physical and psychological factors. A proposed multidisciplinary approach combines low-dose ketamine with pain-focused psychological and somatic therapies to improve quality of life for disabled chronic pain patients. Beyond pain reduction, the treatment aims to reduce suffering and improve pain management, functionality, and quality of life. Adopting a multidisciplinary approach can minimize ketamine exposure and maintain a conservative dosing regimen. Ketamine is used not only for analgesic effects but also to facilitate internal psychological processes of body-mind integration related to pain identity and trauma. The approach is illustrated with three cases treated in a private clinic in Florida, describing original injury, treatment regimen, and short- and longer-term outcomes from the patient's perspective. These preliminary results require replication with validated measures.